Successful intracranial response of lorlatinib after resistance with alectinib and brigatinib in patients with ALK‐positive lung adenocarcinoma: Implications of CNS penetration rate of brigatinib.

Autor: Sato, Yuki¹ (AUTHOR) yuki1130sato@gmail.com, Sato, Yoshiharu² (AUTHOR), Irie, Kei³ (AUTHOR), Nanjo, Shigeki⁴ (AUTHOR), Hara, Shigeo⁵ (AUTHOR), Fujiwara, Satoru⁶ (AUTHOR), Tomii, Keisuke¹ (AUTHOR)

Publikováno v: Thoracic Cancer. Aug2024, Vol. 15 Issue 23, p1772-1775. 4p.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Discovery of AZD4747, a Potent and Selective Inhibitor of Mutant GTPase KRAS^G12C with Demonstrable CNS Penetration.

Autor: Kettle, Jason G., Bagal, Sharan K., Barratt, Derek, Bodnarchuk, Michael S., Boyd, Scott, Braybrooke, Erin, Breed, Jason, Cassar, Doyle J., Cosulich, Sabina, Davies, Michael, Davies, Nichola L., Deng, Chao, Eatherton, Andrew, Evans, Laura, Feron, Lyman J., Fillery, Shaun, Gleave, Emma S., Goldberg, Frederick W., Cortés González, Miguel A., Guerot, Carine

Publikováno v: Journal of Medicinal Chemistry; 7/13/2023, Vol. 66 Issue 13, p9147-9160, 14p

Author Correction: Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations.

Autor: Miyazaki I; Taiho Pharmaceutical Co. Ltd., Tsukuba, Japan. isao-miyazaki@taiho.co.jp., Odintsov I; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA., Ishida K; Taiho Pharmaceutical Co. Ltd., Tsukuba, Japan., Lui AJW; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK., Kato M; Taiho Pharmaceutical Co. Ltd., Tsukuba, Japan., Suzuki T; Taiho Pharmaceutical Co. Ltd., Tsukuba, Japan., Zhang T; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Wakayama K; Taiho Pharmaceutical Co. Ltd., Tsukuba, Japan., Kurth RI; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Cheng R; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Fujita H; Taiho Pharmaceutical Co. Ltd., Tsukuba, Japan., Delasos L; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA., Vojnic M; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Northwell Health Cancer Institute, Lenox Hill Hospital, New York, NY, USA., Khodos I; Antitumor Assessment Core Facility, Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Yamada Y; Taiho Pharmaceutical Co. Ltd., Tsukuba, Japan., Ishizawa K; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Department of Education and Support for Regional Medicine, Tohoku University Hospital, Sendai, Japan., Mattar MS; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Funabashi K; Taiho Pharmaceutical Co. Ltd., Tsukuba, Japan., Chang Q; Antitumor Assessment Core Facility, Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Ohkubo S; Taiho Pharmaceutical Co. Ltd., Tsukuba, Japan., Yano W; Taiho Pharmaceutical Co. Ltd., Tsukuba, Japan., Terada R; Taiho Pharmaceutical Co. Ltd., Tsukuba, Japan., Giuliano C; Helsinn Healthcare SA, Lugano, Switzerland., Lu YC; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Bonifacio A; Helsinn Healthcare SA, Lugano, Switzerland., Kunte S; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Dana Cancer Center, Toledo, OH, USA., Davare MA; Department of Pediatrics, Oregon Health Sciences University, Portland, OR, USA., Cheng EH; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA., de Stanchina E; Antitumor Assessment Core Facility, Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Lovati E; Helsinn Healthcare SA, Lugano, Switzerland., Iwasawa Y; Taiho Pharmaceutical Co. Ltd., Tsukuba, Japan., Ladanyi M; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Somwar R; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. somwarr@mskcc.org.; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. somwarr@mskcc.org.

Publikováno v: Nature cancer [Nat Cancer] 2023 Oct; Vol. 4 (10), pp. 1526.